Evaluation of melatonin effectiveness in the adiuvant treatment of ulcerative colitis

Journal of Physiology and Pharmacology

Volumn 62, Issue 3, 2011, Pages 327-334

  Chojnacki, C ^a   Wisniewska Jarosinska, M ^a   Walecka Kapica, E ^a   Klupinska, G ^a   Jaworek, J ^b   Chojnacki, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Adjuvant treatment; Anxiety; C reactive protein; Inflammatory bowel disease; Melatonin; Ulcerative colitis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CREATININE; ELECTROLYTE; GLUCOSE; HEMOGLOBIN; MELATONIN; MESALAZINE; PLACEBO; THYROTROPIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UREA;

ADJUVANT THERAPY; ADULT; ANXIETY; ARTICLE; BEDTIME DOSAGE; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; ELECTROLYTE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; REMISSION; SCORING SYSTEM; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ULCERATIVE COLITIS; UREA BLOOD LEVEL;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBINS; HUMANS; LOWER GASTROINTESTINAL TRACT; MALE; MEDICATION ADHERENCE; MELATONIN; MESALAMINE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME;

EID: 80355143529     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Adrizzone S, Bianchi Porro G. Inflammatory bowel disease: new insight into pathogenesis and treatment. J Intern Med 2002; 252: 475-496.
2. Adrizzone S, Bianchi Porro G. Comparative tolerability of therapies for ulcerative colitis. Drug Safety 2002; 25: 561-582.
3. Hanauer SB. Update on medical management of inflammatory bowel disease: ulcerative colitis. Rev Gastroenterol Disord 2001; 1: 169-176.
4. Head KA, Jurenka JS. Inflammatory bowel disease part I: Ulcerative colitis-pathophysiology and conventional and alternative treatment. Altern Med Rev 2003; 8: 247-283.
5. Reiter RJ, Tan DX, Manchester LC. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a reviev of the evidence. Cell Biochem Biophys 2001; 34: 247-256.
6. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
7. Skene GJ, Lockey SW, Arendt J. Use of melatonin in the treatment of phase shift and sleep disorders. Adv Exp Med Biol 1999; 467: 79-84.
8. Popoli M. Agomelatine. Innovative pharmalogical approach in depression. CNS Drugs 2009; 23(Suppl 2): 27-34.
9. Akcan A, Kucuk C, Sozuer E, et al. Melatonin reduces bacterial translocation and apoptosis in trinitrobenzene sulphonic acid-induced colitis of rats. World J Gastroenterol 2008; 14: 918-924.
10. Cevik H, Erkanli G, Ercan F, et al. Exposure to continuous darkness ameliorates gastric and colonic inflammation in the rat: both receptor and non-receptor-mediated process. J Gastroenterol Hepatol 2005; 20: 294-303.
11. Cuzzocrea S, Mazzon E, Serraino I, et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 2001; 30: 1-12.
12. Dong WG, Mei Q, Yu JP, et al. Effects of melatonin on the expression of iNOS and COX-2 in rat model of colitis. World J Gastroenterol 2003; 9: 1307-1311.
13. Mei Q, Xu JM, Xiang L, et al. Change on nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad Med J 2005; 81: 667-672.
14. Li JH, Yu JP, Yu HG, et al. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm 2005; 4: 185-193.
15. Marquez EK, Sanchez-Fidalgo S, Calvo JR, et al. Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBSinduced colitis. J Pineal Res 2006; 40: 48-55.
16. Mei Q, Yu JP, Xu JM, et al. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin 2002; 23: 882-886.
17. Necefli A, Tulumoglu B, Gris M, et al. Protective effect of melatonin on TNBS-induced colitis. Dig Dis Sci 2006; 51: 1538-1545.
18. Nosal'ova V, Zeman M, Cerna S, et al. Protective effect of melatonin in acetic acid induced colitis in rats. J Pineal Res 2007; 42: 364-370.
19. Esposito E, Mazzon E, Riccardi L, et al. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin in experimental colitis. J Pineal Res 2008; 45: 166-173.
20. Pentney PT, Bubenik GA. Melatonin reduces the severity of dextran-induced colitis in mice. J Pineal Res 1995; 19: 31-39.
21. Mazzon E, Esposito E, Crisafulli C, et al. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res 2006; 41: 363-373.
22. Malhotra S, Bhasin D, Shafiq N, et al. Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond. Expert Opin Pharmacother 2004; 5: 329-334.
23. Jan JE, O'Donnell ME. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res 1996; 21: 193-199.
24. Schernhammer ES, Rosner B, Willett WC, et al. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev 2004; 13: 936-943.
25. Schernhammer ES, Laden F, Speizer FE, et al. Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 2003; 95: 825-828.
26. Boznanska P, Wichan P, Stêpien A, et al. 24-hour urinary 6-hydroxymelatonin sulfate excretion in patients with ulcerative colitis. Pol Merkur Lekarski 2007; 22: 369-372.
27. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
28. Tosic-Golubovic S, Miljkovic S, Nagorni A, et al. Irritable bowel syndrome, anxiety, depression and personality characteristics. Psychiatr Danub 2010; 22: 418-424.
29. Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory. (BDI-II). 2nd Ed., San Antonio, Psychology Corporation, 1996.
30. Arnau RC, Meagher MW, Norris MP, Bramson R. Psychometric evaluation of the Beck Depression Inventory-II with primary care medical patients. Health Psychol 2001; 20: 112-119.
31. Huether G, Poegeller B, Reimer R, George A. Effects of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 1992; 51: 945-953.
32. Bubenik GA, Brown GM, Hacker RR, Bartos L. Melatonin concentration in the gastrointestinal tissues of bovine fetuses. Acta Vet Brno 2000; 69: 177-182.
33. Messner M, Huether G, Lorf T, et al. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 2001; 69: 543-551.
34. Yaga H, Reiter RJ, Richardson BA. Tryptophan loading increases day time serum melatonin in intact and pinealectomized rats. Life Sci 1993; 52: 1231-1238.
35. Reiter RJ, Tan DX, Mayo M, et al. Neurally mediated and neurally independant beneficial action of melatonin in the gastrointestinal tract. J Physiol Pharmacol 2003; 54(Suppl 4): 111-125.
36. Bubenik GA. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol Signals Recept 2001; 10: 350-366.
37. Sjoblom M, Jedstedt G, Flemstrom G. Peripheral melatonin mediates neural stimulation of duodenal bicarbonate secretion. J Clin Invest 2001; 108: 625-633.
38. Cabeza JA, Alarcon-de-la-Lastra C, Jimenez Z, et al. Melatonin modulates the effects of injury in rats: role of prostaglandins and nitric oxide. Neurol Signals 2003; 12: 71-77.
39. Reiter RJ, Tan DX. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol 2007; 54: 1-9.
40. Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 2008; 45: 235-246.
41. Konturek PC, Konturek SJ, Brzozowski T, et al. Gastroprotective activity of melatonin and its precursor Ltryptophan, against stress-induced and ischaemic-induced lesions is mediated by scavange of oxygen radicals. Scand J Gastroenterol 1997; 32: 433-438.
42. Brzozowski T, Konturek PC, Konturek SJ, et al. The protective action of melatonin on indomethacin-induced gastritis, lesions induced by stress-induced and ischaemicinduced lesions is mediated by scavange of oxygen radicals. Scand J Gastroenterol 1997; 32: 433-438.
43. Koturek SJ, Zayachkiwska O, Hawryluk O, et al. Protective influence of melatonin against acute esophageal lesions involves prostaglandins, nitric oxide and sensory nerves. J Physiol Pharmacol 2007; 58: 371-378.
44. Konturek PC, Konturek SJ, Hahn EG. Duodenal alkaline secretion: its mechanism and role in mucosal protection against gastric acid. Dig Liver Dis 2004; 36: 505-512.
45. Konturek PC, Konturek SJ, Majka J, et al. Melatonin affords protection against lesions induced by ischemia-reperfusion possibly due to its antioxidant and mucosal microcirculatory effects. Eur J Pharmacol 1997; 322: 73-77.
46. Liaw SJ, Chen YC, Ng CJ, et al. Beneficial role of melatonin on microcirculation in endotoxin induced gastropathy in rats: possible implication in nitrogen oxide reduction. J Fomos Med Assae 2002; 101: 129-135.
47. Tamura EK, Silva CL, Markus RP. Melatonin inhibits endothelial nitric oxide production in vitro. J Pineal Res 2006; 41: 267-276.
48. Sener-Muratoglu G, Paskaloglu K, Arbach S, et al. Protective effect of famotidine, omeprazole and melatonin against acetylosalicylic acid-induced gastric damage in rats. Dig Dis Sci 2001; 46: 318-330.
49. Bilici D, Suleyman H, Banoglu ZN, et al. Melatonin prevents ethanol-induced gastric mucosal damage possibly due to its antioxidant effect. Dig Dis Sci 2002; 47: 856-861.
50. Bandyopadhyay D, Bandyopadhyay A, Das PK, et al. Melatonin protects against gastric ulceration and increases efficacy of ranitidine and omeprazole in reducing gastric damage. J Pineal Res 2002; 33: 1-7.
51. Klupinska G, Wisniewska-Jarosinska M, Harasiuk A, et al. Nocturnal secretion of melatonin in patients with upper digestive tract disorder. J Physiol Pharmacol 2006; 57(Suppl 5): 41-50.
52. Stêpien A, Moskwa-Fortuna A, Wisniewska-Jarosinska M, Harasiuk A, Chojnacki J. Melatonin secretion and metabolism in patients with irritable bowel syndrome. Pol Merkur Lek 2009; 26: 440-443.
53. Komarov FI, Rappoport SI, Malinovskaia NK, et al. Melatonin: ulcer disease and seasons of the year. Klin Med 2003; 81: 17-21.
54. Benoulai-Pellissier S. Melatonin is involved in cholecystokinin-induced changes of ileal motility in rats. J Pineal Res 1994; 17: 79-85.
55. Bubenik GA. The effect of serotonin, N-acetylserotonin and melatonin on spontaneous contractions of isolated rat intestine. J Pineal Res 1986; 3: 42-54.
56. Harlow AJ, Weekly BC. Effect of melatonin on the force of spontaneous contractions of in vitro rat small and large intestine. J Pineal Res 1986; 3: 277-284.
57. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and post dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811.
58. El-Sahly M, Norrgard O, Spinnell S. Abnormal colonic endocrine cells in patients with chronic idiopatic slowtransit constipation. Scand J Gastroendocrinol 1999; 34: 1007-1011.
59. Radwan P, Skrzydlo-Radomanska B, Radwan-Kwiatek K, et al. Is melatonin involved in the irritable bowel syndrome? J Physiol Pharmacol 2009; 60(Suppl 3): 67-70.
60. Pentney PT, Bubenik GA. Melatonin reduces the severity of dextran-induced colitis in mice. J Pineal Res 1995; 19: 31-39.
61. Cuzzocrea S, Mazzon E, Serraino I, et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 2001; 30: 1-12.
62. Marquez E, Sanchez-Fidalgo S, Calvo JR, et al. Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBSinduced colitis. J Pineal Res 2006; 40: 48-55.
63. Dong WG, Mei Q, Yu JP, et al. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol 2003; 9: 1307-1311.
64. Necefli A, Tulumoglu B, Giris M, et al. The effect of melatonin on TNBS-induced colitis. Dig Dis Sci 2006; 51: 1538-1545.
65. Mei Q, Yu JP, Xu JM, et al. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin 2002; 23: 882-886.
66. de Souza Pereira R. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. J Pineal Res 2006; 41: 195-200.
67. Werbach MR. Melatonin for the treatment of gastroesophageal reflux disease. Altern Ther Health Med 2008; 14: 54-58.
68. Kandil TS, Mousa AA, El-Gendy AA, Abbas AM. The potential therapeutic effect of melatonin in gastroesphageal disease. BMC Gastroenterol 2010; 10: 7.
69. Rapoport SI, Raikhlin NT, Malinovskaia NK, et al. Ultrastructural changes in cells of the antral gastric mucosa in patients with duodenal ulcers treated with melatonin. Ter Arkh 2003; 75: 10-14.
70. Klupinska G, Poplawski T, Drzewoski J, et al. Therapeutic effect of melatonin in patients with functional dyspepsia. J Clin Gastroenterol 2007; 41: 270-274.
71. Saha L, Malhotra S, Rana S, et al. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol 2007; 41: 29-32.
72. Song GH, Leng PH, Gwee KA, et al. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomized, double blind, placebo controlled study. Gut 2005; 54: 1353-1354.
73. Lu WZ, Gwee KA, Moochhalla S, et al. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2005; 22: 927-934.
74. Terry PD, Villinger F, Bubenik GA, et al. Melatonin and ulcerative colitis: evidence, biological mechanisms and future research. Inflamm Bowel Dis 2009; 15: 134-140.
75. Hardelan R, Pandi-Perumal SR. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab 2005; 10: 2: 22.